Skip to main
  1. Stocks
  2. Insulet
  3. Forecast
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 18%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Insulet is attractive because its Omnipod franchise combines a differentiated tubeless, pharmacy-channel patch pump with a large, underpenetrated global diabetes market, supporting a multi-year growth runway and roughly 31% share in a 14MM-patient opportunity. Recent execution reinforces that view: 3Q revenue of $842M rose 19.6% cc, adj. EPS reached $1.99, gross margin expanded to 74.2%, and operating margin reached 22.0%, while FY26 guidance was raised at the low end on improved OUS momentum. Even with softer U.S. growth and future competition risks, the board’s $1B buyback authorization and management’s continued path toward double-digit growth, margin expansion, and stronger EPS drop-through underscore durable fundamental value.

Bears say

Insulet is facing a deteriorating fundamental backdrop as management guided 2027 U.S. growth to the low end of the prior 9%-14% range and total company growth to modestly below the mid-teens, signaling decelerating demand rather than a reacceleration. The core issue is weakening Type 2 retention and churn, while stable pricing and utilization offer little offset and international growth is set to slow as the Dash-to-Omnipod 5 conversion matures beyond 80% and large launches are anniversaried. At the same time, intensifying tubeless competition and trialing, combined with limited contribution from new launches and an apparent credibility overhang from a suspended long-term framework, leaves downside risk to margins, estimates, and valuation.

Insulet (PODD) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 18% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Insulet (PODD) Analyst Forecast & Price Prediction

Get the latest Insulet (PODD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Insulet (PODD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 22 analysts, Insulet (PODD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Insulet (PODD) Analyst Forecast & Price Prediction

Get the latest Insulet (PODD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Insulet (PODD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PODD stock data and trends